Given these findings, an ongoing phase I clinical trial (NCT03026517) aims to assess the safety and efficacy of phenformin plus BRAF and MEK inhibitors in patients with BRAF mutant advanced melanoma. This evidence concerns the gene MAP2K7 and melanoma.